LUPIN

LIMITED: CO. ENTERS EXCLUSIVE LICENSE AGREEMENT WITH VISUS THERAPEUTICS FOR YUVEZZITM IN EUROPE; TOTAL POTENTIAL CONSIDERATION UP TO €75 MILLION INCLUDING STRATEGIC INVESTMENT AND MILESTONE PAYMENTS.